| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Treatment failure by day 28a | |||
| Kaplan–Meier estimates % risk | 0 | 61.1 | <.001 |
| 95% confidence interval | 0–7.7 | 46.8–75.6 | |
| n/N | 0/46 | 26/42 | |
| Early treatment failure | |||
| n/N (%) | 0 | 4/49 (8.2) | <.001 |
| Late treatment failure | |||
| Total n/N (%) | 0 | 22/42 (52.4) | <.001 |
| Clinical n/N (%) | … | 15/42 (35.7) | |
| Parasitological n/N (%) | … | 7/42 (16.7) | |
| Day of recurrenceb | |||
| median | … | 23 | … |
| (interquartile range) [range] | … | (14–28)[7–28] | |
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Treatment failure by day 28a | |||
| Kaplan–Meier estimates % risk | 0 | 61.1 | <.001 |
| 95% confidence interval | 0–7.7 | 46.8–75.6 | |
| n/N | 0/46 | 26/42 | |
| Early treatment failure | |||
| n/N (%) | 0 | 4/49 (8.2) | <.001 |
| Late treatment failure | |||
| Total n/N (%) | 0 | 22/42 (52.4) | <.001 |
| Clinical n/N (%) | … | 15/42 (35.7) | |
| Parasitological n/N (%) | … | 7/42 (16.7) | |
| Day of recurrenceb | |||
| median | … | 23 | … |
| (interquartile range) [range] | … | (14–28)[7–28] | |
a There were no additional treatment failures after day 28; therefore, Kaplan–Meier estimates at day 42 were the same as at day 28.
b Late treatment failure only.
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Treatment failure by day 28a | |||
| Kaplan–Meier estimates % risk | 0 | 61.1 | <.001 |
| 95% confidence interval | 0–7.7 | 46.8–75.6 | |
| n/N | 0/46 | 26/42 | |
| Early treatment failure | |||
| n/N (%) | 0 | 4/49 (8.2) | <.001 |
| Late treatment failure | |||
| Total n/N (%) | 0 | 22/42 (52.4) | <.001 |
| Clinical n/N (%) | … | 15/42 (35.7) | |
| Parasitological n/N (%) | … | 7/42 (16.7) | |
| Day of recurrenceb | |||
| median | … | 23 | … |
| (interquartile range) [range] | … | (14–28)[7–28] | |
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Treatment failure by day 28a | |||
| Kaplan–Meier estimates % risk | 0 | 61.1 | <.001 |
| 95% confidence interval | 0–7.7 | 46.8–75.6 | |
| n/N | 0/46 | 26/42 | |
| Early treatment failure | |||
| n/N (%) | 0 | 4/49 (8.2) | <.001 |
| Late treatment failure | |||
| Total n/N (%) | 0 | 22/42 (52.4) | <.001 |
| Clinical n/N (%) | … | 15/42 (35.7) | |
| Parasitological n/N (%) | … | 7/42 (16.7) | |
| Day of recurrenceb | |||
| median | … | 23 | … |
| (interquartile range) [range] | … | (14–28)[7–28] | |
a There were no additional treatment failures after day 28; therefore, Kaplan–Meier estimates at day 42 were the same as at day 28.
b Late treatment failure only.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
